News UK's Claret Capital raises €575m for European biotechs London-based Claret Capital Partners has closed its fourth European Growth Capital Fund, raising €575m for "Europe's boldest innovators."
News Novo Nordisk's IL-6 drug flunks two more heart trials Novo Nordisk has opted to discontinue two late-stage trials of IL-6 inhibitor ziltivekimab in heart failure, after taking an interim look at the data.
News Novartis hit as Lp(a) drug fails cardio outcomes trial Novartis shares have slipped after it revealed its Lp(a)-targeted drug, pelacarsen, failed to reduce cardiovascular risks in a major phase 3 trial.
News FDA overrides adcomm and approves AZ's oral SERD The FDA has gone against the advice of its own expert advisors and approved AstraZeneca's Etcamah as a frontline treatment for breast cancer.
News Major trial of Roche Alzheimer's drug kicks off in Europe The PrevenTRON trial of Roche's Brainshuttle drug trontinemab in preclinical Alzheimer's disease has gotten underway in the UK.
News Merck rare tumour drug Ezmekly backed for NHS use Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.